Mission

ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value.  Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.

Staff Only

Remember Me
TwitterLinkedinFacebookFeed
ICER publishes report on all management options for low-risk prostate cancer
ICER has completed a draft report on the comparative clinical effectiveness and comparative value of all major management options for low-risk prostate cancer.  The report summarizes findings from three previous ICER appraisals, and also includes the results of new decision-analytic modeling incorporating all treatment approaches as well as a clinician decision guide. .
 
The report is published as a draft; public comments are encouraged.  The comment period, originally scheduled to end October 16, 2009, has been extended to November 13, 2009.  Comments may be submitted online at the report page or via e-mail to This e-mail address is being protected from spambots. You need JavaScript enabled to view it .